Frederick A Ofosu

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi request reprint Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus
    Sora Ludwig
    Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835 715 McDermot Ave, Winnipeg, Man, Canada
    Diabetes Res Clin Pract 70:110-8. 2005
  2. doi request reprint Plasma-derived biological medicines used to promote haemostasis
    Frederick A Ofosu
    Canadian Blood Services, Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC 3N26, Hamilton, ON, Canada L8N 3Z5
    Thromb Haemost 99:851-62. 2008
  3. doi request reprint The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro
    F A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Haemophilia 18:917-25. 2012
  4. doi request reprint Management of bleeding disorders: basic science
    F A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Haemophilia 18:8-14. 2012
  5. doi request reprint A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins
    Frederick A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 107:201-14. 2012
  6. doi request reprint Early intraplatelet signaling enhances the release of human platelet PAR-1 and -4 amino-terminal peptides in response to thrombin
    Frederick A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, and Canadian Blood Services, Hamilton, Ontario L8N 3Z5, Canada
    Biochemistry 48:1562-72. 2009
  7. doi request reprint Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin
    Frederick A Ofosu
    Canadian Blood Services, Hamilton, Ontario, Canada
    J Biol Chem 283:26886-93. 2008
  8. doi request reprint Differences in the safety profiles of two low-molecular-weight heparins
    Frederick A Ofosu
    Canadian Blood Services and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Thromb Haemost 99:989-90. 2008
  9. doi request reprint The United States Food and Drugs Administration approves a generic enoxaparin
    Frederick A Ofosu
    McMaster University, Hamilton, Ontario L8N 3Z5, Canada
    Clin Appl Thromb Hemost 17:5-8. 2011
  10. ncbi request reprint Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment
    Frederick A Ofosu
    Canadian Blood Services and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
    Thromb Haemost 96:568-77. 2006

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus
    Sora Ludwig
    Diabetes Research Group, Department of Internal Medicine, University of Manitoba, 835 715 McDermot Ave, Winnipeg, Man, Canada
    Diabetes Res Clin Pract 70:110-8. 2005
    ..The results suggest that simvastatin reduces in vivo prothrombinase activity and PAI-1 levels in type 2 DM patients. These actions may contribute to the protective properties of simvastatin against ischemic events in diabetic patients...
  2. doi request reprint Plasma-derived biological medicines used to promote haemostasis
    Frederick A Ofosu
    Canadian Blood Services, Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC 3N26, Hamilton, ON, Canada L8N 3Z5
    Thromb Haemost 99:851-62. 2008
    ..It also considers approaches employed to minimize infectivity of biological medicines derived from human and animal plasmas and to manage patients who develop antibodies (inhibitors) to clotting factor concentrate infusions...
  3. doi request reprint The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro
    F A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Haemophilia 18:917-25. 2012
    ..The FVIII:Ag fraction in Kogenate and Advate that cannot bind VWF appears to be inactive as it has no measureable FVIII:C activity in the presence of added VWF in vitro...
  4. doi request reprint Management of bleeding disorders: basic science
    F A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Haemophilia 18:8-14. 2012
    ....
  5. doi request reprint A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins
    Frederick A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 107:201-14. 2012
    ....
  6. doi request reprint Early intraplatelet signaling enhances the release of human platelet PAR-1 and -4 amino-terminal peptides in response to thrombin
    Frederick A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, and Canadian Blood Services, Hamilton, Ontario L8N 3Z5, Canada
    Biochemistry 48:1562-72. 2009
    ..We propose that unidentified ATP-dependent phosphorylation reactions catalyzed by PKC help to generate the platelet-derived proteinase that propagates human platelet PAR-1 and -4 activation by the three agonists...
  7. doi request reprint Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin
    Frederick A Ofosu
    Canadian Blood Services, Hamilton, Ontario, Canada
    J Biol Chem 283:26886-93. 2008
    ....
  8. doi request reprint Differences in the safety profiles of two low-molecular-weight heparins
    Frederick A Ofosu
    Canadian Blood Services and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Thromb Haemost 99:989-90. 2008
  9. doi request reprint The United States Food and Drugs Administration approves a generic enoxaparin
    Frederick A Ofosu
    McMaster University, Hamilton, Ontario L8N 3Z5, Canada
    Clin Appl Thromb Hemost 17:5-8. 2011
    ..The safety issues that have led to withdrawal of some generic LMWHs from some Asian and South American countries mandate the need for a broad consensus defining the minimum attributes copies of LMWHs required for efficacy and safety...
  10. ncbi request reprint Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment
    Frederick A Ofosu
    Canadian Blood Services and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
    Thromb Haemost 96:568-77. 2006
    ....
  11. ncbi request reprint The blood platelet as a model for regulating blood coagulation on cell surfaces and its consequences
    F A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
    Biochemistry (Mosc) 67:47-55. 2002
    ..Activated platelets participate in tumor development by releasing several factors that positively (and negatively) regulate blood vessel formation...
  12. ncbi request reprint Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin
    Frederick A Ofosu
    Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, 1200 Main Street West, 3N26, Hamilton, Ont, Canada L8N 3Z5
    Transfus Apher Sci 28:265-8. 2003
    ..This review will consider the direct and indirect evidence that apparently support the idea that PAR-1 and PAR-4 activation by thrombin drives platelet activation..
  13. ncbi request reprint Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation
    Theodore E Warkentin
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Thromb Haemost 94:958-64. 2005
    ..DTIs with a relatively low affinity for thrombin require high plasma concentrations to double the APTT; these higher plasma concentrations, in turn, quench more of the thrombin generated in the PT, thereby more greatly prolonging the PT...
  14. doi request reprint A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins
    Frederick A Ofosu
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Clin Ther 31:679-91. 2009
    ....
  15. ncbi request reprint Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells
    Jianping Wen
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, L8N 3Z5 Canada
    J Gene Med 8:362-9. 2006
    ..In this study we report the use of mouse fetal G8 myoblasts secreting hFIX in hemophilia mice...
  16. ncbi request reprint Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice
    Jianping Wen
    Research and Development, Canadian Blood Services, McMaster University, Hamilton, Ontario, L8N 3Z5 Canada
    J Gene Med 9:1002-10. 2007
    ..As a step towards the treatment of human patients, in this study we report the implantation of encapsulated human primary myoblasts secreting hFIX in hemophilia B mice...
  17. pmc A trypsin-like platelet protease propagates protease-activated receptor-1 cleavage and platelet activation
    F A Ofosu
    Canadian Red Cross Society, Blood Services, Hamilton, Ontario, L8N 1H8 Canada and McMaster University, Department of Pathology, HSC 3N26, 1200 Main St West, Hamilton, Ontario, L8N 3Z5 Canada
    Biochem J 336:283-5. 1998
    ..HCl (pefabloc SC) and soybean trypsin inhibitor, but not by inhibitors of calpain, cysteine proteases or metalloproteases. Thus, a trypsin-like platelet protease propagates SFLLRN-dependent PAR-1 cleavage and platelet activation...
  18. ncbi request reprint Human platelet thrombin receptors. Roles in platelet activation
    F A Ofosu
    Canadian Blood Services, McMaster University, Hamilton, Ontario, Canada
    Hematol Oncol Clin North Am 14:1185-98, x. 2000
    ....
  19. ncbi request reprint Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis
    G Hortelano
    Canadian Blood Services, Canada
    Haemophilia 7:207-14. 2001
    ..Thus, while this study revealed the feasibility of this gene therapy approach to treat severe haemophilia B, it also highlights the importance of using safer cell lines to prevent tumour development...
  20. doi request reprint Safety and efficacy of thrombin-JMI: a multidisciplinary expert group consensus
    Mohit Bhandari
    McMaster University, Hamilton, ON, Canada
    Clin Appl Thromb Hemost 17:39-45. 2011
    ..Its use has a reported association with the development of antibodies to coagulation factors with limited evidence to the clinical significance...
  21. ncbi request reprint Therapeutic levels of human factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A
    Carmen García-Martín
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    J Gene Med 4:215-23. 2002
    ..It has been shown that encapsulated myoblasts can deliver therapeutic levels of Factor IX (FIX) in mice. The delivery of human Factor VIII (hFVIII) in mice using microcapsules was evaluated in this study...
  22. doi request reprint Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins
    Ilya Mukovozov
    Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC 3N26, Hamilton, ON, Canada L8N 3Z5
    Thromb Haemost 99:874-82. 2008
    ..The main aim of this review is to summarize some of the factors that are known to contribute to the immunogenicity of recombinant therapeutic proteins...
  23. ncbi request reprint Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits
    William P Sheffield
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Br J Haematol 126:565-73. 2004
    ....
  24. doi request reprint Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism
    R Selby
    Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Thromb Res 124:281-7. 2009
    ..Major trauma induces a hypercoagulable state, which is frequently complicated by pathological thrombosis. However the sequential changes in coagulation markers and their relationship to clinical thrombosis have been poorly characterized...
  25. ncbi request reprint Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C)
    J Freedman
    Transfusion Medicine, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Am J Hematol 69:192-9. 2002
    ....
  26. ncbi request reprint Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity
    R Devraj-Kizuk
    Canadian Red Cross Blood Transfusion Service, Department of Pathology, McMaster University, Hamilton, Ontario
    Blood 72:1518-23. 1988
    ....
  27. doi request reprint Current use of biologicals in thrombosis and haemostasis
    Frederick A Ofosu
    Thromb Haemost 99:805-6. 2008
  28. doi request reprint Propagating factor IX-producing hepatocytes for haemophilia B therapy
    Frederick A Ofosu
    Thromb Haemost 99:799-800. 2008